跳至主要内容
临床试验/NCT04412044
NCT04412044已完成4 期

Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

KU Leuven0 个研究点目标入组 22 人开始时间: 2016年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
KU Leuven
入组人数
22
主要终点
Airway inflammation

研究概览

简要总结

22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements were analyzed.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • FEV1 < 80% in the last 12 months
  • use of high dose inhaled corticosteroids (ICS) in combination with other additional medication or continuous use of oral corticosteroids (OCS)
  • at least 2 exacerbations in the last 12 months
  • at least 300 blood eosinophils/µl once in the last 12 months and at the time of inclusion
  • Anti-IL5 treatment prescribed by the physician

排除标准

  • Not completing all visits

研究组 & 干预措施

Asthmatics

Experimental

Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment

干预措施: Mepolizumab Injection [Nucala] (Drug)

结局指标

主要结局

Airway inflammation

时间窗: Day 1 and after 6 months

Bronchial airway inflammation. Differential cell count will be performed on sputum samples, determining eosinophilic (\>3% eosinophils, \<61% neutrophils), neutrophilic (\<3% eosinophils and \>61% neutrophils), pauci-granulocytic (\<3% eosinophils and \<61% neutrophils) and mixed granulocytic airway inflammation (\>3% eosinophils and \>61% neutrophils).

Change in Forced Expiratory Volume in 1 seconds (FEV1)

时间窗: Day 1 and after 6 months

The forced expiratory Volume in 1 second will be measured using spirometry

次要结局

  • Change in asthma control(Day 1 and after 6 months)
  • Cytokine pattern in the airways(Day 1 and after 6 months)
  • Cytokine pattern in the bloodstream(Day 1 and after 6 months)
  • Biomarkers for airway inflammation(Day 1 and after 6 months)

研究者

发起方
KU Leuven
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tatjana Decaesteker

Principal Investigator

KU Leuven

相似试验